Methods for inhibiting drug degradation
    1.
    发明授权
    Methods for inhibiting drug degradation 有权
    抑制药物降解的方法

    公开(公告)号:US08952056B2

    公开(公告)日:2015-02-10

    申请号:US12919012

    申请日:2009-02-23

    摘要: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.

    摘要翻译: 提供抑制细胞色素P450酶的方法,其可用于通过防止细胞色素P450对药物或其它分子的降解来改善疾病的治疗。 提供的药物组合物可用作增效剂以改善药代动力学,增强生物利用度,并增强经细胞色素P450酶体内降解的药物的治疗效果。

    Benzofuran derived HIV protease inhibitors
    4.
    发明授权
    Benzofuran derived HIV protease inhibitors 有权
    苯并呋喃衍生的HIV蛋白酶抑制剂

    公开(公告)号:US07981929B2

    公开(公告)日:2011-07-19

    申请号:US12050125

    申请日:2008-03-17

    CPC分类号: C07D493/04

    摘要: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

    摘要翻译: 提供抗驱虫和多药耐药的逆转录病毒蛋白酶抑制剂。 还提供了包含这些化合物的药物组合物,以及使用这些化合物治疗哺乳动物HIV感染的方法。

    AMINO ACID INHIBITORS OF CYTOCHROME P450
    5.
    发明申请
    AMINO ACID INHIBITORS OF CYTOCHROME P450 有权
    氨基酸P450的氨基酸抑制剂

    公开(公告)号:US20110124578A1

    公开(公告)日:2011-05-26

    申请号:US12919009

    申请日:2009-02-23

    IPC分类号: A61K38/12

    摘要: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that eases can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.

    摘要翻译: 提供抑制细胞色素P450酶的方法,其可用于通过防止细胞色素P450对药物或其它分子的降解来改善疾病的治疗。 提供了药物组合物,其可以作为增强剂以改善药代动力学,增强生物利用度,并增强经细胞色素P450酶进行体内降解的药物的治疗效果。

    Long Acting Biologically Active Conjugates
    7.
    发明申请
    Long Acting Biologically Active Conjugates 审中-公开
    长效生物活性缀合物

    公开(公告)号:US20070207952A1

    公开(公告)日:2007-09-06

    申请号:US10550715

    申请日:2004-03-24

    摘要: The invention provides biologically active compounds that may be reacted with macromolecules, such as albumin, to form covalent linked complexes wherein the resulting complexes exhibit a desired biological activity in vivo. More specifically, the complexes are isolated complexes comprising a biologically active moiety covalently bound to a linking group and a protein. The complexes are prepared by conjugating a biologically active moiety, for example, a renin inhibitor or a viral fusion inhibitor peptide, with purified and isolated protein. The complexes have extended lifetimes in the bloodstream as compared to the unconjugated molecule, and exhibit biological activity for extended periods of time as compared to the unconjugated molecule. The invention also provides anti-viral compounds that are inhibitors of viral infection and/or exhibit anti-fusiogenic properties. In particular, this invention provides compounds having inhibiting activity against viruses such as human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) and that have extended duration of action for the treatment of viral infections.

    摘要翻译: 本发明提供可与大分子如白蛋白反应的生物活性化合物以形成共价连接的络合物,其中所得的复合物在体内显示出所需的生物学活性。 更具体地,复合物是包含与连接基团和蛋白质共价结合的生物活性部分的分离的复合物。 通过将生物活性部分例如肾素抑制剂或病毒融合抑制剂肽与纯化和分离的蛋白质缀合来制备复合物。 与非共轭分子相比,复合物在血液中的寿命延长,与非共轭分子相比,延长的时间段具有生物活性。 本发明还提供了抗病毒化合物,其是病毒感染的抑制剂和/或表现出抗融合生物学特性。 特别地,本发明提供了对人体免疫缺陷病毒(HIV),呼吸道合胞病毒(RSV),人副流感病毒(HPV),麻疹病毒(MeV)和猿猴免疫缺陷病毒(SIV)等病毒具有抑制活性的化合物, 延长了治疗病毒感染的时间。